von Coburg Y, Kottke T, Weizel L, Ligneau X, Stark H
Johann Wolfgang Goethe Universität, Institut für Pharmazeutische Chemie, Biozentrum, ZAFES/CMP, Max-von-Laue-Strasse 9, 60438 Frankfurt, Germany.
Bioorg Med Chem Lett. 2009 Jan 15;19(2):538-42. doi: 10.1016/j.bmcl.2008.09.012. Epub 2008 Sep 7.
Histamine H3 receptor (H3R) antagonists have some antipsychotic properties although the clear molecular mechanism is still unknown. As actually the most effective and less side effective antipsychotics are drugs with multiple targets we have designed typical and atypical neuroleptics with an additional histamine H3 pharmacophore. The 4-(3-piperidinopropoxy)phenyl pharmacophore moiety has been linked to amitriptyline, maprotiline, chlorpromazine, chlorprothixene, fluphenazine, and clozapine. Amide, amine and ester elements have been used generally to maintain or slightly shift affinity at dopamine D(2)-like receptors (D2 and D3), to decrease affinity at histamine H(1) receptors, and to obtain H3R ligands with low nanomolar or subnanomolar affinity. Change of effects at D(1)-like receptors (D1) and (D5) were heterogeneous. With these newly profiled compounds different antipsychotic properties might be achieved.
组胺H3受体(H3R)拮抗剂具有一些抗精神病特性,尽管其确切的分子机制仍不清楚。由于实际上最有效且副作用较小的抗精神病药物是具有多个靶点的药物,我们设计了带有额外组胺H3药效基团的典型和非典型抗精神病药物。4-(3-哌啶基丙氧基)苯基药效基团部分已与阿米替林、马普替林、氯丙嗪、氯普噻吨、氟奋乃静和氯氮平相连。酰胺、胺和酯元素通常用于维持或轻微改变对多巴胺D(2)样受体(D2和D3)的亲和力,降低对组胺H(1)受体的亲和力,并获得具有低纳摩尔或亚纳摩尔亲和力的H3R配体。对D(1)样受体(D1)和(D5)的作用变化是异质性的。使用这些新描述的化合物可能会实现不同的抗精神病特性。